2024年制药业趋势展望报告：产业合作、市场成熟度与数字化未来

2024 Pharma Trends Outlook: Collaboration,Market Maturity,and Digital Futures 2024 Pharma Trends in Focus 7.Pricing, cost, and patients -balancing the pharma trinity8.Evidence-basedherbal medicines9.The future of B2Bpharma marketing10.AcceleratingAlzheimer’s research11.What 2023 drug approvalsmean for 202412.Middle East rising:an emerging market in focus 1.Generative AI and supplychain digitisation2.Consumer drivenpackaging innovations3.Mature qualitymanagement and control4.Biotech and R&Doutsourcing practices:investing and acquiring5.Collaborative sustainabilityby all, for all6.Making excipients great again Contributors Introduction The 2023 CPHI Online Pharma Trends Reportdelved into critical issues, from reshoringdrug production to manufacturingreimagined through Pharma 4.0,exploring how the industry grappledwith challenges like supply chaindisruption, security, and escalatingdrug manufacturing costs. Amidstthese hurdles, 2023 provided a chancefor the pharmaceutical supply chainto proactively address issues, markinga shift towards resilience and qualitymanagement. priority for the industry. Cross-industrycollaboration for sustainability initiatives,the US FDA’s Quality Management Maturityprogram, and patient-centric packagingdesigns are leading the pharmaceuticalindustry into the future. Underpinning thesestrategies is the increased digitisation ofthe supply chain with generative AI andmachine-learning technologies. enhance efficiency in delivering medicinesto patients securely and on time. The CPHI Online 2024 Pharma TrendsReport, sponsored by Arvato Systems,dissects emerging trends. From the impactof generative AI on the supply chain tomature quality management plans forbiomanufacturers, excipient marketgrowth, biologics outsourcing, and more,these expert insights provide a valuableoutlook for those navigating the globalsupply chain in 2024. Arvato CSDBis a leading example of thedigitisation of the industry – a softwareproviding proven serialisation solutionsto over 80 pharmaceutical companies,ensuring seamless implementation oflegal requirements against counterfeitmedicines. This positive shift is anticipatedto extend into 2024, with initiatives andguidance fostering industry investmentand collaboration. The goal is clear: Klaus Fetzer Learning from the past, the industryis embracing a proactive mindset,propelling it into a new era of supplychain robustness. Protecting consumersfrom supply shortages, adulteration,and counterfeit products remains a top Managing Director Health & Public,Arvato Systems Generative AIand supply chaindigitisation Generative AIand supply chaindigitisation enabling better inventory management and minimisingrisks of shortages or excess inventory.” Big Data Analytics was one of our 2023 Pharma TrendsReport predictions. Many expect it to continue pushing theindustry towards digitalisation in efforts to reduce productlead times and manufacturing costs [1]. 2024 will see the evolution of digital technologies for supplychain management, according toStefan Moch, VP Healthof Arvato Systems, who sees this manifesting in two majorways. “One of the two topics is Big Data Analytics in thepharmaceutical industry,” he states. “Big Data Analyticsis revolutionising pharmaceutical manufacturing, witha significant impact on quality control and regulatorycompliance. Manufacturers employ data analytics tomonitor and control product quality by analysing data fromvarious sensors and equipment. Additionally, productionprocesses are optimised through the identification ofbottlenecks, waste reduction, and efficiency improvements.Data analysis is integral to supply chain management, Data-oriented manufacturing for pharmaceuticals hasbeen acknowledged by regulatory bodies as a meansof not only reducing costs and time-to-market, but alsoensuring quality and efficiency of processes. With manysteps in the pharmaceutical manufacturing processgenerating large amounts of data from numeroussensors and equipment, the ability to gather, sort, store,and analyse all this information will differentiate leadingmanufacturers from the rest. the supply chain – transparency is a critical element forsustainability and resiliency, and frankly, we are not movingfast enough or with sufficient purpose. Too much data withno data architecture will impede the industry’s progress.” Moch also cites cybersecurity as a leading trend for thedigitalisation of the pharmaceutical supply chain. “A‘taboo subject’, it is one that should be the focus of everycompany, especially in an industry with such sensitivedata,” he states. “In a time where not only criminals butalso governments use cyber-crime for their purposes,cybersecurity plays a critical role in the pharmaceuticalsector, ensuring the protection of sensitive data such aspatient records, research findings, and valuable intellectualproperty.” “In biopharma specifically, it has been challenging tobalance demand and supply post-COVID,” commentsNicola Coles, Ph